National Cancer Institute Common Terminology Criteria for Adverse Events grading and management of CRS from blinatumomab
| Grade . | Criteria* . | Management† . |
|---|---|---|
| Grade 1 | Fever ± constitutional symptoms | Symptom management without interruption of therapy |
| Grade 2 | Hypotension not requiring pressors, responding to fluids | Symptomatic treatment with intravenous fluids, respiratory support, anti-inflammatory, narcotics; interrupting blinatumomab can be considered |
| Hypoxia responsive to <40% O2 | ||
| Grade 3 | Hypotension managed with one pressor | Discontinue blinatumomab until resolution; resume at 9 µg/d and then escalate to 28 µg/d if recurrence of CRS after 7 d |
| Hypoxia requiring ≥40% O2 | ||
| Grade 4 | Life-threatening complications | Discontinue blinatumomab permanently; if refractory to corticosteroids, tocilizumab may be considered |
| Urgent intervention indicated | ||
| Grade 5 | Death | — |
| Grade . | Criteria* . | Management† . |
|---|---|---|
| Grade 1 | Fever ± constitutional symptoms | Symptom management without interruption of therapy |
| Grade 2 | Hypotension not requiring pressors, responding to fluids | Symptomatic treatment with intravenous fluids, respiratory support, anti-inflammatory, narcotics; interrupting blinatumomab can be considered |
| Hypoxia responsive to <40% O2 | ||
| Grade 3 | Hypotension managed with one pressor | Discontinue blinatumomab until resolution; resume at 9 µg/d and then escalate to 28 µg/d if recurrence of CRS after 7 d |
| Hypoxia requiring ≥40% O2 | ||
| Grade 4 | Life-threatening complications | Discontinue blinatumomab permanently; if refractory to corticosteroids, tocilizumab may be considered |
| Urgent intervention indicated | ||
| Grade 5 | Death | — |